<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02048397</url>
  </required_header>
  <id_info>
    <org_study_id>FIM-BRO-2013-01</org_study_id>
    <nct_id>NCT02048397</nct_id>
  </id_info>
  <brief_title>Pulmonary Rehabilitation Program (PRP) Versus PRP Plus Nutritional Supplementation in Patients With Bronchiectasis</brief_title>
  <acronym>FIM-BRO-2013</acronym>
  <official_title>A Pilot Study of Pulmonary Rehabilitation Program (PRP) Versus PRP Plus Nutritional Supplementation in Patients With Bronchiectasis: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundación Pública Andaluza Progreso y Salud</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The effect of Pulmonary Rehabilitation in patients with bronchiectasis (BC) is not&#xD;
      sufficiently studied. The aim of this study is to assess the clinical and biological response&#xD;
      of a Pulmonary Rehabilitation Program (PRP) for 12 weeks in BC vs PRP plus hyperproteic oral&#xD;
      nutritional supplement enriched with beta-hydroxy-beta-methylbutyrate (HMB).&#xD;
&#xD;
      Methods: single center randomized controlled trial, parallel treatment design: Participants&#xD;
      will be randomized assigned either will receive (n=14) PRP for 60 minutes, two supervised&#xD;
      sessions per week in the hospital and one unsupervised session at home vs PRP (n=14) plus ONS&#xD;
      (one can per day).&#xD;
&#xD;
      Outcome assessments will be performed at baseline, 12 weeks and 24 weeks:&#xD;
&#xD;
      1.- effort capacity &amp;#8211;cardiopulmonary exercise test-, 2.- body composition&#xD;
      (anthropometry, lean body mass by dual energy X-ray absorptiometry and bioimpedance, phase&#xD;
      angle), 3.- peripheral muscle strength (dynamometry and respiratory -PEM (maximum expiratory&#xD;
      pressure)and PIM (minimum expiratory pressure)-), 4.- spirometry, 5.- respiratory symptoms&#xD;
      (bronchorrhea, dyspnoea, exacerbations),6.- level of physical activity (IPAQ questionnaire&#xD;
      plus objective physical activity (WGT3X)), 7.- quality of life (QOL-B-Spain) ,&#xD;
      8.-psychological symptoms (HASD) and 9.- biological markers of inflammation (leptin,&#xD;
      adiponectin, interleukin-6, tumor necrosis factor-alpha, ultrasensitive C-reactive protein,&#xD;
      GPR55 (G protein-coupled receptor 55) RNAm (messenger ribonucleic acid) expression in white&#xD;
      blood cells) and oxidation (total antioxidant capacity, superoxide dismutase activity,&#xD;
      8-iso-prostaglandin F2a, Thiobarbituric acid reactive substances).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in oxygen uptake at peak exercise (VO2max) in cardiopulmonary exercise test (Before and after Rehabilitation-at 3 and 6 months)</measure>
    <time_frame>3rd and 6th month visits</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body composition</measure>
    <time_frame>3rd and 6th month visits</time_frame>
    <description>Anthropometry, lean body mass by dual energy X-ray absorptiometry and bioimpedance.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Peripheral muscle strength</measure>
    <time_frame>3rd and 6th month visits</time_frame>
    <description>Dynamometry</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in respiratory symptoms (bronchorrhea, dyspnea, exacerbations) at 6 months.</measure>
    <time_frame>3rd and 6th month visits</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Level of physical activity</measure>
    <time_frame>3rd and 6th month visits</time_frame>
    <description>IPAQ questionnaire plus objective physical activity</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of life</measure>
    <time_frame>3rd and 6th month visits</time_frame>
    <description>QOL-B-Spain</description>
  </other_outcome>
  <other_outcome>
    <measure>biological markers of Biological markers of inflammation and oxidation</measure>
    <time_frame>3rd and 6th month visits</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Bronchiectasis</condition>
  <arm_group>
    <arm_group_label>Pulmonary Rehabilitation (PRP)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Pulmonary Rehabilitation (PRP)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pulmonary Rehabilitation plus oral nutritional supplement</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Hyperproteic oral nutritional supplement enriched with beta-hydroxy-beta-methylbutyrate (HMB)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pulmonary Rehabilitation</intervention_name>
    <arm_group_label>Pulmonary Rehabilitation (PRP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Hyperproteic oral nutritional supplement enriched with beta-hydroxy-beta-methylbutyrate</intervention_name>
    <arm_group_label>Pulmonary Rehabilitation plus oral nutritional supplement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients ages from 18-80 (both included)&#xD;
&#xD;
          -  Patients with bronchiectasis, not cystic fibrosis bronchiectasis.&#xD;
&#xD;
          -  Bronchiectasis diagnosed by high resolution computed tomography (HRCT). of the chest&#xD;
&#xD;
          -  Patients followed in Bronchiectasis and Cystic Fibrosis Units in the Hospital.&#xD;
&#xD;
          -  BMI &gt; 18.5 in patients under 65 years old, and &gt; 20kg/m2 in patients over this age.&#xD;
&#xD;
          -  Ambulatory patients.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of oral corticoids.&#xD;
&#xD;
          -  Respiratory exacerbation. If a patient had a respiratory exacerbation or a recent&#xD;
             hospital admission, their participation will be postponed for at least 60 days til any&#xD;
             acute disease is resolved.&#xD;
&#xD;
          -  Prior oral or parenteral supplements intake.&#xD;
&#xD;
          -  Traumatological, neurological or cardiovascular diseases that prevent patients from&#xD;
             performing the training.&#xD;
&#xD;
          -  Life threatening hemoptysis in the past year.&#xD;
&#xD;
          -  Patients with cancer, major surgery in the previous three months, participating in&#xD;
             another study, patients who are pregnant or may become pregnant, patients with acute&#xD;
             intestinal disease, acute heart failure, severe hepatic failure or dialysis.&#xD;
&#xD;
          -  Gastrectomy, gastroparesis or other alterations of gastric emptying.&#xD;
&#xD;
          -  Enteral tube feeding, galactosemia, Fructosemia.&#xD;
&#xD;
          -  Allergy or known sensitivity to any ingredient of the enteral formula.&#xD;
&#xD;
          -  Cystic fibrosis.&#xD;
&#xD;
          -  Included in active list for transplantation.&#xD;
&#xD;
          -  Drug or alcohol abuse.&#xD;
&#xD;
          -  No informed consent signed.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GABRIEL OLVEIRA, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Andaluz Health Service</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gabriel Olveira</name>
      <address>
        <city>Malaga</city>
        <zip>29009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Clin Nutr. 2015 Oct 19. pii: S0261-5614(15)00255-1. doi: 10.1016/j.clnu.2015.10.001. [Epub ahead of print]</citation>
  </reference>
  <verification_date>August 2013</verification_date>
  <study_first_submitted>January 15, 2014</study_first_submitted>
  <study_first_submitted_qc>January 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2014</study_first_posted>
  <last_update_submitted>March 15, 2016</last_update_submitted>
  <last_update_submitted_qc>March 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bronchiectasis.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiectasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

